Market Overview
The oral anticoagulants market is expanding beyond atrial fibrillation to include venous thromboembolism (VTE) treatment and prevention, cancer-associated thrombosis, and peripheral artery disease. DOACs are increasingly used for these indications. The market is projected to grow through 2030, driven by growing clinical evidence, expanding approvals, and increasing awareness....
English
Arabic
French
Spanish
Portuguese
Deutsch
Turkish
Dutch
Italiano
Russian
Romaian
Portuguese (Brazil)